Redox-associated miRNAs regulated by anti-TNBC compounds DET and DETD-35 in MDA-MB-231 cells
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA746246 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Triple-negative breast cancer is a difficult breast cancer subtype to treat that lacks targeted therapies. Specific miRNAs have been reported to be involved in cancer progression and their significance in cancer diagnosis and anti-cancer drug development has been highlighted; however, whether redox-associated miRNAs are potential targets of anti-cancer drugs or bioactive phytocompounds, which deregulate cancer cell activity through modulating ROS dynamics is unclear. This study addressed the anti-TNBC cell effect of phytosesquiterpene lactones deoxyelephantopin (DET) and its derivative DETD-35 by which redox-associated miRNAs were responsive and regulated as demonstrated by comparative miRNA microarray analysis and ROS scavenging approaches.
2024-07-13 | GSE180000 | GEO
Project description:Single-cell transcriptional lineage tracing TNBC MDA-MB-231
| PRJEB53139 | ENA
Project description:Triple-negative breast cancer (TNBC) is aggressive and difficult, and few targeted therapies are available to treat this patient population. The androgen receptor (AR) has emerged as a potential target in breast cancer. Newer generation AR inhibitors, such as Seviteronel (Sevi), are unique in their ability to inhibit AR both directly and by blocking upstream androgen synthesis. The purpose of this study was to investigate the pre-clinical activity of Sevi in TNBC and further explore the effectiveness of targeting both androgen biosynthesis and AR activity in combination with other downstream acting agents. AR overexpressing (AR+) TNBC cell lines, xenografts and androgen responsive patient-derived xenograft (PDX) models were using to show how effectively Sevi inhibits AR activity and cell/tumor proliferation. Single cell RNA-sequencing of the AR+ cell line MDA-MB-453 illustrated heterogeneity in AR levels and identified cell cycle pathway activation in ARHigh versus ARLow expressing cells. Combination treatment with the cell cycle CDK4/6 inhibitor abemaciclib and Sevi showed synergy in AR+ TNBC cells and increased effectiveness, compared to each drug alone, in an AR+ TNBC xenograft model. While cell cycle inhibitors have been approved for use in hormone-receptor positive breast cancer, our studies suggest that these drugs may be equally effective in AR+ TNBC cells, especially when combined with AR antagonists. Implications. These data suggest that targeting AR signaling at multiple points throughout the pathway may be an effective was to treat patients with AR+ TNBC.
2020-06-12 | GSE152315 | GEO
Project description:microRNAs have been shown to be involved in the pathogenesis of TNBC as important regulators of cell proliferation and apoptosis. However, whether the activation of retinoic acid receptor alpha (RARα), a transcription factor, is involved in mediating transcriptional regulation of microRNAs remains elusive. Here, we investigated the differentially expressed miRNAs in triple negative breast cancer cell line MDA-MB-231 overexpressing a phosphorylation-defective mutant RARαS77A, which mimicked activated RARα, in comparison to non-transfected control cells.
2021-05-05 | GSE160295 | GEO
Project description:Mutant p53 can acquires oncogenic properties supporting tumor growth, metastases and chemoresistance, by reprogramming cancer cell transcriptome, proteome and metabolome. To investigate what is the gene expression network regulated by mutant p53, we silenced its expression in MDA-MB-231 Triple Negative Breast Cancer (TNBC) cell line. We then performed gene expression profiling analysis using data obtained from RNA-seq of MDA-MB 231.
2023-10-06 | GSE214493 | GEO
Project description: Not available
| S-EPMC11242520 | biostudies-literature
Project description:In the article "Fra-1 regulates its target genes via binding to remote enhancers without exerting major control on chromatin architecture in triple negative breast cancers" by Bejjani et al., we used NG Capture-C approach to identify regulatory elements interacting with the promoters of 35 Fra-1 regulated genes in the triple negative breast cancer cell line MDA-MB-231
2021-02-23 | GSE146824 | GEO
Project description:Transcriptomic profiling of MDA-MB-231 cells treated with cytostatic compounds
| PRJNA684559 | ENA
Project description:Triple-Negative breast cancer (TNBC) is an aggressive subtype of breast cancer that is associated with poor prognosis due to its propensity to form metastases. Unfortunately, the current treatment options are limited to chemotherapy such that identification of actionable targets are needed. The receptor tyrosine kinase AXL plays a role in the tumor cell dissemination and its expression in TNBC correlates with poor patients? survival. Here, we explored whether exploiting an AXL knockdown gene signature in TNBC cells may offer an opportunity for drug repurposing. To this end, we queried the PharmacoGx pharmacogenomics platform with an AXL gene signature which revealed Phenothiazines, a class of Dopamine Receptors antagonists (Thioridazine, Fluphenazine and Trifluoperazine) typically used as anti-psychotics. We next tested if drugs may be active to limit growth and metastatic progression of TNBC cells, similarly to AXL depletion. We found that the Phenothiazines were able to reduce cel l invasion, proliferation and viability, and also increased apoptosis of TNBC cells in vitro. Mechanistically, these drugs did not affect AXL activity but instead reduced PI3K/AKT/mTOR and ERK signaling. When administered to mice bearing TNBC xenografts, these drugs showed were able to reduce tumor growth and metastatic burden. Collectively, these results suggest that these antipsychotics are novel anti-tumor and anti-metastatic agents that could potentially be repurposed, in combination with standard chemotherapy, for use in TNBC.
2019-04-01 | GSE120268 | GEO
Project description:AR heterogeneity in TNBC MDA-MB-453 cells
| PRJNA638948 | ENA